Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,142.3
3.5 (0.11%)

 

  • STI Straits Times Index
    3,142.3
    3.5 (0.11%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,514.0
    -0.6 (-0.04%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,086.4
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,381.2
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,775.8
    -194.5 (-0.70%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,097.0
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 145.9M
  • Value: 155.1M
  • Rise: 122
  • Fall: 51
  • Unch: 588

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.110+0.001
MM2 Asia0.071+0.004
Metal Component0.059+0.002
Olam Intl1.280-0.060
Leader Env0.080+0.002
GSS Energy0.068+0.001
KTL Global^0.119-0.003
Singtel2.250+0.020
Serial System0.146+0.010
Mercurius0.064+0.002

World Indices

World Indices
Name Last Change
Nasdaq 14,660.6 -180.1
HSI 25,345.3 +258.9
HSCEI 9,039.5 +159.9
Jakarta 6,097.0
Nikkei 225 27,763.2 -207.0
SSE Comp 3,345.4 -35.8
Shanghai A 3,506.2 -37.5
Shanghai B 255.3 -1.6
KOSPI 3,238.3 +5.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Pharmesis Intl PHARMESIS INTERNATIONAL LTD.
Quotes 10 Minutes Delayed. Updated at 28 Jul 2021 08:41
Last (SGD): 0.150 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 0.150
Buy Price 0.126 Sell Price 0.300
Buy Volume ('000) 20.0 Sell Volume ('000) 3.9
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.05126 Trailing EPS (SGD) e -0.05126 NAV (SGD) b 0.4954
PE a - Trailing PE f - Price / NAV b 0.3028
Dividend (SGD) d - Cash In Hand (SGD) g 0.1337 Issued & Paid-up Shares c 23,000,000
Dividend Yield (%) d - Price / Cash In Hand g 1.122 Treasury Shares h -
Beta - 75 Daysi -0.530 R-Squared - 75 Days(%)i 0.71 Market Cap (M) 3.450
Beta - 500 Daysi -0.371 R-Squared - 500 Days (%)i 0.37 Enterprise Value (M) 3.970
Piotroski F Score 4 Exchange Code BFK Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 72.6252 6-Month VWAP 0.176 Free Float (%) -
Under CPF Investment Scheme (CPFIS) Yes
Sector & Industry Manufacturing - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Index Components FTSE ST Fledgling Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 14 Apr 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Pharmesis Intl SGX 3.450 - - 0.3028 -
Industry Medical & Biotechnology SGX 967.262 20.286 19.452 1.3912 1.992
Pharmaceuticals: Major SGX 89.901 2431.015 115.115 3.5954 0.691
Index FTSE ST Fledgling Index SGX 115.774 2166.819 354.039 0.7310 2.212
Local Peer IX Biopharma SGX 175.349 - - 6.6952 -
Local Peer Hyphens Pharma SGX 94.635 15.358 15.355 2.0064 1.968
Global Peer JOHNSON & JOHNSON NYSE 454,682.844 30.901 25.591 - 2.304
Global Peer PFIZER INC NYSE 235,662.749 24.507 21.248 3.4343 3.614
Global Peer ELI LILLY AND COMPANY NYSE 233,599.553 37.716 38.342 33.8616 1.212
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 222,311.234 27.378 24.717 4.1137 2.111
Global Peer ABBVIE INC NYSE 208,343.311 45.729 40.980 15.1965 4.101
Global Peer MERCK & CO INC NYSE 197,120.871 27.893 28.048 7.3157 3.183
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 158,910.004 24.661 23.638 17.1905 1.501
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 150,767.936 - - 4.0092 2.739
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 99,425.997 13.486 14.644 4.8479 5.236
Global Peer WUXI APPTEC HKEx 471,989.686 142.211 99.076 11.2754 0.220
Other Global Peers TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), HANSOH PHARMA (HKEx), VIATRIS INC (NASDAQ), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), REPLIGEN CORP (NASDAQ), CUREVAC NV (NASDAQ), SINOPHARM (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), HUTCHMED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SH PHARMA (HKEx), JUNSHI BIO (HKEx), HYGEIA HEALTH (HKEx), REMEGEN-B (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CMS (HKEx), AKESO-B (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), INNOCARE-B (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), BAIYUNSHAN PH (HKEx), ALLAKOS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), CHINARES PHARMA (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), KARUNA THERAPEUTICS INC (NASDAQ), SIMCERE PHARMA (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), TRAD CHI MED (HKEx), NEKTAR THERAPEUTICS (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), CHINAGRANDPHARM (HKEx), IGM BIOSCIENCES INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), OPKO HEALTH INC (NASDAQ), CSTONE PHARMA-B (HKEx), EVEREST MED-B (HKEx), HENLIUS (HKEx), ERASCA INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CARSGEN-B (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP (HKEx), HEPALINK (HKEx), OCUMENSION-B (HKEx), ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), Y-MABS THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), UNITED LAB (HKEx), ANTENGENE-B (HKEx), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), Kimia Farma Tbk. (IDX), REPARE THERAPEUTICS INC (NASDAQ), TONGRENTANGCM (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), GENERATION BIO CO (NASDAQ), IMMUNOTECH-B (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), PETIQ INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), SCICLONE PHARMA (HKEx), CKLIFE SCIENCES (HKEx), PHIBRO ANIMAL HEALTH CORP (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), ANNOVIS BIO INC (NYSE American), KEROS THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), GH RESEARCH PLC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), SHINEWAY PHARM (HKEx), ANNEXON INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ZHAOKE OPHTH-B (HKEx), EVOLUS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), AC IMMUNE SA (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), HUA MEDICINE-B (HKEx), TARSUS PHARMACEUTICALS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), Soho Global Health Tbk. (IDX), SIGA TECHNOLOGIES INC (NASDAQ), PHARVARIS NV (NASDAQ), INOZYME PHARMA INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), IGBB (Bursa), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), RACE ONCOLOGY LTD (ASX), STARPHARMA HOLDINGS LIMITED (ASX), PROVENTION BIO INC (NASDAQ), BEYONDSPRING INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), XOMA CORP (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), BIOMEA FUSION INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), ATHENEX INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), 89BIO INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), THERATECHNOLOGIES INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), DURECT CORP (NASDAQ), BSTEAD (Bursa), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), GAMIDA CELL LTD (NASDAQ), TOT BIOPHARM-B (HKEx), VERRICA PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), VINCERX PHARMA INC (NASDAQ), PHARMA (Bursa), 180 LIFE SCIENCES CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), NEXIMMUNE INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), FUSEN PHARM (HKEx), IMMUNIC INC (NASDAQ), MUSTANG BIO INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), OBSEVA SA (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), IP (SET), LANNETT CO INC (NYSE), ONCTERNAL THERAPEUTICS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), CH BIOTECH SER (HKEx), PHASEBIO PHARMACEUTICALS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), LANTERN PHARMA INC (NASDAQ), IMARA INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), POLYPID LTD (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), ODONATE THERAPEUTICS INC (NASDAQ), ZHONGZHIPHARM (HKEx), RECCE PHARMACEUTICALS LTD (ASX), AQUESTIVE THERAPEUTICS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), NOVAN INC (NASDAQ), ENTERA BIO LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), EYENOVIA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), GALECTO INC (NASDAQ), PROPHASE LABS INC (NASDAQ), CRESO PHARMA LTD (ASX), MEDIWOUND LTD (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), NEW RAY MEDIC (HKEx), MOLECULIN BIOTECH INC (NASDAQ), CHARMACY PHAR (HKEx), GRAYBUG VISION INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), Phapros Tbk. (IDX), DARE BIOSCIENCE INC (NASDAQ), PAK FAH YEOW (HKEx), NC HEALTHCARE (HKEx), EDESA BIOTECH INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), BIOHLDG (Bursa), NOVA (Bursa), MODERN CHI MED (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), EXOPHARM LTD (ASX), SYNAPTOGENIX INC (NASDAQ), MANNATECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), INVION LTD (ASX), NEP INTERLONG (HKEx), ASSERTIO HOLDINGS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), ACURX PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), VIRIOS THERAPEUTICS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), ADIAL PHARMACEUTICALS INC (NASDAQ), PALLA PHARMA LTD (ASX), TBG DIAGNOSTICS LTD (ASX), CNS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), PURAPHARM (HKEx), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), SANAI HEALTH GP (HKEx), PANBELA THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), JCT (SET), VALLON PHARMACEUTICALS INC (NASDAQ), SUNZEN (Bursa), PHARMAXIS (ASX), AVENUE THERAPEUTICS INC (NASDAQ), EXTRAWELL PHAR (HKEx), PETROS PHARMACEUTICALS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), TALI DIGITAL LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), ACRUX (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), ISLAND PHARMACEUTICALS LTD (ASX), SINOLIFE UTD (HKEx), SUDA PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), CELLMID LIMITED (ASX), FARMAFORCE LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days ---
20 Days --0.070
-31.82 %
Medium Term Return 3 Months --0.065
-30.23 %
6 Months --0.170
-53.12 %
1 Year --0.160
-51.61 %
Long Term Return 2 Years --0.055
-26.83 %
3 Years --0.050
-25.00 %
5 Years --0.250
-62.50 %
Annualised Return Annualised --
-17.81 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.132 - 0.450 Change From 1 Year Low +0.018 % Change From 1 Year Low (%) +13.64
Change From 1 Year High -0.300 % Change From 1 Year High (%) -66.67
2 Years Range 0.115 - 0.625 Change From 2 Years Low +0.035 % Change From 2 Years Low (%) +30.43
Change From 2 Years High -0.475 % Change From 2 Years High (%) -76.00
5 Years Range 0.115 - 0.625 Change From 5 Years Low +0.035 % Change From 5 Years Low (%) +30.43
Change From 5 Years High -0.475 % Change From 5 Years High (%) -76.00
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

The Company was incorporated in Singapore on 29 September 2003 under the name of Sinopharm Pte Ltd and it changed its name to Pharmesis International Pte Ltd on 16 April 2004. It adopted its current name on 30 August 2004.Pharmesis specializes in the manufacture of pharmaceutical products, including western medicine and Traditional Chinese Medicine ('TCM’’).Under its two subsidiaries, Kinna Pharm and Longlife, it specializes in the manufacturing of pharmaceutical products in the form of tablets, granules, pills, etc, including TCM formulated products for the treatment of illnesses relating to the liver and gall bladder. Its two main products are ATT tablets and Gansu granules. Additionally, its business also includes the research and development, production, sale and marketing of pharmaceutical products. These pharmaceutical products are sold in China and they include western medicine products under the '?? ' brand, while its TCM formulated products are sold under the '???? ' brand.Leveraging its research and development capabilities and in-house expertise in pharmaceutical products for the treatment of illnesses relating to the liver and gall bladder, Pharmesis has successfully obtained the license to produce ATT tablets in China. Similarly, it is the only Group with the right to produce Gansu granules from Ganhuangcao in China.With sales and marketing network of approximately 900 sales personnel across China, its products can be found in 2,000 hospitals in many cities within China. The Group's two production facilities are located in Chengdu and Gulin, China.

IPO Performance

Listing Date 06 Oct 2004 Full Subscription Rate (x) 11.45
No of Placement Shares (M) 46.20 No of Public Offer Shares (M) 3.80 Public Offer Subscription Rate (x) 138.48
IPO Price (SGD) a 2.500 First Day Close (SGD) a 3.900 First Week Close (SGD) a 3.700
Current vs IPO Price (%) -94.00 First Day Gain (%) +56.00 First Week Gain (%) +48.00
Notes:
  1. Adjusted for the following: Share Consolidation 1 for 10 on 27/08/2015

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2020 Dec 2020 Part 1(2.14 MB)
Annual Report 2019 Dec 2019 Part 1(5.25 MB)
Annual Report 2018 Dec 2018 Part 1(6.72 MB)
Annual Report 2017 Dec 2017 Part 1(6.64 MB)
Annual Report 2016 Dec 2016 Part 1(1.05 MB)
Part 2(0.12 MB)
Annual Report 2015 Dec 2015 Part 1(10.35 MB)
Annual Report 2014 Dec 2014 Part 1(1.16 MB)
Annual Report 2013 Dec 2013 Part 1(1.00 MB)
Annual Report 2012 Dec 2012 Part 1(4.42 MB)
Annual Report 2011 Dec 2011 Part 1(0.72 MB)
Annual Report 2010 Dec 2010 Part 1(1.32 MB)
Annual Report 2009 Dec 2009 Part 1(2.02 MB)
Annual Report 2008 Dec 2008 Part 1(1.00 MB)
Annual Report 2007 Dec 2007 Part 1(1.34 MB)
Annual Report 2006 Dec 2006 Part 1(0.03 MB)
Part 2(2.25 MB)
Part 3(0.23 MB)
Annual Report 2005 Dec 2005 Part 1(0.88 MB)
IPO Prospectus
IPO Prospectus 2004 Oct 2004 Part 1(14.34 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
27 Jul 2021 0.150 0.150 0.150 0.150 - -
26 Jul 2021 0.150 0.150 0.150 0.150 - -
23 Jul 2021 0.150 0.150 0.150 0.150 - -
22 Jul 2021 0.150 0.150 0.150 0.150 - -
21 Jul 2021 0.150 0.150 0.150 0.150 - -
19 Jul 2021 0.150 0.150 0.150 0.150 12,000 0.1500
16 Jul 2021 0.150 0.150 0.150 0.150 - -
15 Jul 2021 0.150 0.150 0.150 0.150 - -
14 Jul 2021 0.150 0.150 0.150 0.150 - -
13 Jul 2021 0.150 0.150 0.150 0.150 - -
12 Jul 2021 0.150 0.150 0.150 0.150 1,000 0.1500
09 Jul 2021 0.132 0.132 0.132 0.132 5,000 0.1320
08 Jul 2021 0.220 0.220 0.220 0.220 - -
07 Jul 2021 0.220 0.220 0.220 0.220 - -
06 Jul 2021 0.220 0.220 0.220 0.220 - -
05 Jul 2021 0.220 0.220 0.220 0.220 - -
02 Jul 2021 0.220 0.220 0.220 0.220 - -
01 Jul 2021 0.220 0.220 0.220 0.220 - -
30 Jun 2021 0.220 0.220 0.220 0.220 - -
29 Jun 2021 0.220 0.220 0.220 0.220 - -
28 Jun 2021 0.220 0.220 0.220 0.220 - -
25 Jun 2021 0.220 0.220 0.220 0.220 - -
Summary
Current 2 Weeks
(13 Jul 2021 to 27 Jul 2021)
0.150 0.150 0.150 0.150 12,000 -
Previous 2 Weeks
(29 Jun 2021 to 12 Jul 2021)
0.220 0.220 0.150 0.150 6,000 -
4 Weeks from
(01 Jun 2021 to 28 Jun 2021)
0.220 0.220 0.150 0.220 2,500 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.